作者
Do‐Youn Oh,Aiwu Ruth He,Mohamed Bouattour,Takuji Okusaka,Shukui Qin,Li‐Tzong Chen,Masayuki Kitano,Choong‐kun Lee,Jin Won Kim,Ming-Huang Chen,Thatthan Suksombooncharoen,Masafumi Ikeda,Myung Ah Lee,Jen‐Shi Chen,Piotr Potemski,Howard A. Burris,Vikas Ostwal,Suebpong Tanasanvimon,Chigusa Morizane,Renata Zaucha,Mairéad G. McNamara,Antonio Avallone,Juan E Cundom,В. В. Бредер,Benjamin Tan,Satoshi Shimizu,David Tougeron,Ludovic Evesque,Mila Petrova,David B. Zhen,Roopinder Gillmore,Vineet Gupta,Farshid Dayyani,Joon Oh Park,Gary L. Buchschacher,Felipe Rey,Hyosung Kim,Julie Wang,Claire Morgan,Nana Rokutanda,Magdalena Żotkiewicz,Arndt Vogel,Juan W. Valle
摘要
In the preplanned interim analysis of the TOPAZ-1 study, durvalumab plus gemcitabine-cisplatin significantly improved overall survival versus placebo plus gemcitabine-cisplatin in participants with advanced biliary tract cancer. We aimed to report updated overall survival and safety data from TOPAZ-1 with additional follow-up and data maturity beyond the interim analysis.
爱静静
zzzyyy
乐乐乐乐乐乐
浅尝离白
shinysparrow
kento
景辣条
竹筏过海
YifanWang
鬼见愁
吃不饱星球球长
徐叽钰
华仔
睡觉晒太阳
不配.
mmyhn
eternity136
从容芮
账户已注销
rosalieshi
皖公网安备34019202002308
